STOCK TITAN

Hims & Hers Health (HIMS) Financials

HIMS NYSE
Trailing 12 months to September 30, 2026
Revenue $2.9B +29.8% YoY
Net Income -$190.8M -242.6% YoY
EPS (Diluted) -$0.83 -256.6% YoY
Free Cash Flow $8.2M -93.1% YoY
Market Cap $4.0B as of Nov 18, 2026
Price / Sales 1.4x on $2.9B revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 11.2x on $355.3M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HIMS SEC filings page.

Hims & Hers Health, Inc. (HIMS) reported $2.9B in revenue over the twelve months to Sep 30, 2026, up 29.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HIMS FY2025

Rapid growth now requires heavier financing and reinvestment, while reported profit remains positive but converts less efficiently into free cash.

Revenue grew 59.0% in FY2025, but net income increased only 1.8%, so expansion is no longer translating into proportionate bottom-line growth. Operating cash flow of $300M exceeded net income, yet free cash flow fell 71.0%, showing that earnings still become operating cash but much less remains after investment.

The balance sheet changed from debt-free in FY2024 to a 1.8x debt-to-equity ratio in FY2025, while liabilities reached 74.9% of assets; growth was accompanied by a materially more leveraged funding structure. A 1.9x current ratio means near-term assets still exceed near-term obligations, but it does not offset the longer-term leverage shift.

Gross margin fell 5.6 percentage points to 73.8% while operating margin edged up 0.3 percentage points to 4.5%; operating performance improved despite weaker gross economics. SG&A represented 50.8% of revenue versus 57.3% in FY2024, indicating that lower overhead consumption helped absorb the margin pressure.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 49 / 100
Financial Health Score 49/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Hims & Hers Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
35

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Hims & Hers Health, Inc. scores 35/100 on it among other operating companies.

Growth
96

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Hims & Hers Health, Inc. scores 96/100 on it among other operating companies.

Leverage
16

Hims & Hers Health, Inc.'s net debt of $744.0M, being $972.6M of long-term debt less $228.6M of cash, came to 4.65 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Hims & Hers Health, Inc. scores 16/100 among other operating companies measured the same way.

Liquidity
57

Hims & Hers Health, Inc. held $1.90 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.90. Liquidity ranks operating companies on that ratio, and Hims & Hers Health, Inc. scores 57/100 among other operating companies.

Cash Flow
52

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Hims & Hers Health, Inc. scores 52/100 on it among other operating companies.

Returns
39

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Hims & Hers Health, Inc. scores 39/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.87

Hims & Hers Health, Inc. scores 2.87, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $4.0B against total liabilities of $1.6B. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/8

Hims & Hers Health, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed
2.34x

For every $1 of reported earnings, Hims & Hers Health, Inc. generates $2.34 in operating cash flow ($300.0M OCF vs $128.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$890.4M
YoY+48.6%
QoQ+18.2%
5Y CAGR+64.4%

Hims & Hers Health, Inc. generated $890.4M in revenue in Q3 2026. This represents an increase of 48.6% from the same quarter a year earlier. Against the prior quarter it is up 18.2%.

EBITDA
-$27.9M
YoY-194.8%
QoQn/m
5Y CAGRn/m

Hims & Hers Health, Inc.'s EBITDA was -$27.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 194.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$33.0M
YoY-309.5%
QoQn/m
5Y CAGRn/m

Hims & Hers Health, Inc. reported a net loss of $33.0M in Q3 2026. This represents a decrease of 309.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.14
YoY-333.3%
QoQn/m
5Y CAGRn/m

Hims & Hers Health, Inc. earned -$0.14 per diluted share (EPS) in Q3 2026. This represents a decrease of 333.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$26.0M
YoY-67.3%
QoQn/m

Hims & Hers Health, Inc. generated $26.0M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 67.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$605.6M
YoY+75.1%
QoQ-0.7%
5Y CAGR+56.4%

Hims & Hers Health, Inc. held $605.6M in cash against $1.4B in long-term debt as of Q3 2026.

Shares Outstanding
Diluted avg 234M

Hims & Hers Health, Inc. had a weighted average of 234M diluted shares in Q3 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
57.2%
YoY-16.6pp
QoQ-6.6pp
5Y change-16.8pp

Hims & Hers Health, Inc.'s gross margin was 57.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 16.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.6 percentage points.

Operating Margin
-7.4%
YoY-9.4pp
QoQ+5.5pp
5Y change+29.9pp

Hims & Hers Health, Inc.'s operating margin was -7.4% in Q3 2026, reflecting core business profitability. This is down 9.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.5 percentage points.

Net Margin
-3.7%
YoY-6.3pp
QoQ+7.7pp
5Y change+17.8pp

Hims & Hers Health, Inc.'s net profit margin was -3.7% in Q3 2026, showing the share of revenue converted to profit. This is down 6.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.7 percentage points.

Return on Equity
-9.3%
YoY-12.0pp
QoQ+17.3pp
5Y change-4.8pp

Hims & Hers Health, Inc.'s quarterly ROE was -9.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 12.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 17.3 percentage points.

Capital Allocation

Capital Expenditures
$39.4M
YoY-43.1%
QoQ+22.0%

Hims & Hers Health, Inc. invested $39.4M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 43.1% from the same quarter a year earlier. Against the prior quarter it is up 22.0%.

R&D Spending

Not reported for Q3 2026.

Share Buybacks

Not reported for Q3 2026.

HIMS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HIMS quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$890.4M+48.6%$753.2M+38.2%$608.1M+3.8%$617.8M+28.4%$599.0M+49.2%$544.8M+72.6%$586.0M+110.7%$481.1M+95.1%
Cost of Revenue$381.2M+142.9%$272.4M+111.8%$211.3M+36.1%$173.4M+55.4%$156.9M+87.5%$128.6M+117.9%$155.3M+216.5%$111.6M+162.2%
Gross Profit$509.2M+15.2%$480.8M+15.5%$396.8M-7.9%$444.4M+20.3%$442.1M+39.1%$416.2M+62.2%$430.7M+88.0%$369.5M+81.1%
SG&A Expenses$398.8M+27.5%$427.6M+50.0%$331.7M+18.5%$314.2M+16.8%$312.8M+37.9%$285.1M+53.7%$279.8M+69.5%$269.1M+70.1%
Operating Income-$66.1M-660.2%-$97.2M-463.7%-$78.3M-235.3%$9.2M-50.6%$11.8M-47.2%$26.7M+142.3%$57.9M+484.6%$18.6Mn/m
EBITDA-$27.9M-194.8%-$67.7M-282.1%-$56.4M-185.2%$27.3M+10.6%$29.5M+10.2%$37.2M+153.4%$66.2M+412.8%$24.7M+992.0%
Income Tax-$13.2Mn/m-$6.3Mn/m-$9.4M-185.7%-$2.2Mn/m-$3.6Mn/m-$9.7M-7700.0%$11.0M+763.5%-$3.7M-492.6%
Net Income-$33.0M-309.5%-$86.3M-303.0%-$92.1M-286.1%$20.6M-20.8%$15.8M-79.1%$42.5M+219.7%$49.5M+344.7%$26.0M+1990.4%
EPS (Basic)-$0.14-300.0%-$0.37-294.7%-$0.40-281.8%$0.09-18.2%$0.07-80.0%$0.19+216.7%$0.22+340.0%$0.11+1000.0%
EPS (Diluted)-$0.14-333.3%-$0.37-317.6%-$0.40-300.0%$0.08-20.0%$0.06-81.3%$0.17+183.3%$0.20+300.0%$0.10+900.0%
Diluted Shares (Avg)234M-6.0%232M-9.7%228M-7.4%N/A249M+5.8%257M+9.4%247M+7.5%N/A

Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.

HIMS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HIMS quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$3.5B+58.8%$3.6B+93.3%$2.3B+154.2%$2.2B+204.5%$2.2B+270.8%$1.9B+290.8%$891.7M+99.0%$707.5M+60.4%
Current Assets$1.3B+56.3%$1.4B+2.1%$1.0B+133.9%$767.6M+93.9%$845.3M+159.0%$1.4B+366.0%$447.0M+70.8%$395.8M+49.3%
Cash & Equivalents$605.6M+75.1%$609.8M-45.8%$222.3M-18.8%$228.6M+3.6%$345.8M+108.9%$1.1B+769.8%$273.7M+160.1%$220.6M+128.2%
Short-Term Investments$106.6M-62.5%$231.2M+1054.3%$528.6M+980.2%$348.9M+337.9%$284.0M+220.7%$20.0M-79.6%$48.9M-50.2%$79.7M-35.9%
Inventory$107.8M+1.8%$87.8M-38.1%$79.1M+3.9%$80.1M+24.4%$106.0M+115.8%$141.8M+249.4%$76.1M+155.1%$64.4M+186.8%
Accounts ReceivableN/AN/AN/A$32.1M+426.2%N/AN/AN/A$6.1M-9.0%
Long-Term Investments$0-100.0%$0n/m$0n/m$351.3Mn/m$438.3Mn/m$0n/m$0n/m$0n/m
Goodwill$1.1B+328.4%$1.1B+835.6%$342.8M+191.2%$278.3M+146.9%$259.2M+130.0%$117.8M+6.2%$117.8M+6.2%$112.7M+1.7%
Total Liabilities$3.2B+93.2%$3.3B+151.3%$1.8B+431.7%$1.6B+599.1%$1.7B+918.6%$1.3B+1009.3%$342.4M+230.5%$230.8M+137.6%
Current Liabilities$1.4B+218.5%$1.5B+444.8%$618.8M+120.7%$404.4M+82.7%$450.8M+195.3%$272.2M+150.5%$280.4M+200.4%$221.4M+150.2%
Non-Current Liabilities$1.8B+46.1%$1.8B+74.7%$1.2B+1836.1%$1.2B+12689.2%$1.2B+12461.8%$1.0B+10471.4%$62.1M+502.8%$9.5M+8.8%
Long-Term Debt$1.4B+40.8%$1.4B+40.8%$974.1M$972.6Mn/m$971.0M$969.5MN/A$0
Total Equity$355.3M-38.8%$324.1M-42.4%$446.2M-18.8%$540.9M+13.5%$581.0M+32.0%$562.7M+55.5%$549.3M+59.4%$476.7M+38.6%
Retained Earnings-$325.2Mn/m-$292.2Mn/m-$205.9Mn/m-$113.8Mn/m-$134.4Mn/m-$150.1Mn/m-$192.7Mn/m-$242.1Mn/m

HIMS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HIMS quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$65.4M-56.0%-$35.9Mn/m$89.4M-18.1%$61.3M-29.0%$148.7M+74.4%-$19.1M-135.7%$109.1M+322.2%$86.4M+293.0%
Depreciation & Amortization$38.2M+116.3%$29.5M+181.7%$22.0M+165.3%$18.1M+198.5%$17.7M+303.1%$10.5M+187.3%$8.3M+175.8%$6.1M+128.0%
Stock-Based Compensation$64.5M+60.5%$42.1M+17.9%$36.9M+48.3%N/A$40.2M+61.3%$35.7M+48.6%$24.9M+30.6%N/A
Capital Expenditures$39.4M-43.1%$32.3M-35.9%$36.3M-38.5%$63.9M+137.5%$69.3M+1074.6%$50.4M+740.0%$59.0M+321.4%$26.9M
Free Cash Flow$26.0M-67.3%-$68.2Mn/m$53.1M+5.9%-$2.6M-104.4%$79.4M+0.1%-$69.5M-246.1%$50.1M+323.1%$59.5M
Investing Cash Flow-$55.4Mn/m$84.5Mn/m-$15.4Mn/m-$83.7Mn/m-$887.4Mn/m-$21.1Mn/m-$32.8M-351.5%-$17.2M-183.1%
Financing Cash Flow-$18.9Mn/m$341.8M-61.6%-$77.9Mn/m-$97.5Mn/m-$39.0Mn/m$889.2Mn/m-$23.0Mn/m-$13.7Mn/m
Share BuybacksN/AN/AN/A$80.5M+1508.0%$9.5M-68.4%$0-100.0%$0-100.0%$5.0M+150.4%

Not reported in any period shown, so not listed: Dividends Paid.

HIMS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HIMS quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin57.2%-16.6pp63.8%-12.6pp65.3%-8.3pp71.9%-4.9pp73.8%-5.4pp76.4%-4.9pp73.5%-8.9pp76.8%-5.9pp
Operating Margin-7.4%-9.4pp-12.9%-17.8pp-12.9%-22.8pp1.5%-2.4pp2.0%-3.6pp4.9%+1.4pp9.9%+6.3pp3.9%+4.0pp
Net Margin-3.7%-6.3pp-11.5%-19.3pp-15.2%-23.6pp3.3%-2.1pp2.6%-16.2pp7.8%+3.6pp8.4%+4.4pp5.4%+4.9pp
Return on Equity-9.3%-12.0pp-26.6%-34.2pp-20.6%-29.7pp3.8%-1.7pp2.7%-14.5pp7.5%+3.9pp9.0%+5.8pp5.5%+5.1pp
Return on Assets-0.9%-1.6pp-2.4%-4.6pp-4.1%-9.6pp1.0%-2.7pp0.7%-11.8pp2.3%-0.5pp5.5%+3.1pp3.7%+3.4pp
Current Ratio0.92-1.0x0.93-4.0x1.69+0.1x1.90+0.1x1.88-0.3x4.98+2.3x1.59-1.2x1.79-1.2x
Debt-to-Equity3.85+2.2x4.21+2.5x2.181.80+1.8x1.671.72N/A0.00
Liabilities-to-Equity8.98+6.1x10.20+7.9x4.08+3.5x2.98+2.5x2.84+2.5x2.34+2.0x0.62+0.3x0.48+0.2x
Asset Turnover0.250.0x0.21-0.1x0.27-0.4x0.29-0.4x0.27-0.4x0.29-0.4x0.660.0x0.68+0.1x
FCF Margin2.9%-10.3pp-9.1%+3.7pp8.7%+0.2pp-0.4%-12.8pp13.3%-6.5pp-12.8%-27.8pp8.6%+4.3pp12.4%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Hims & Hers Health, Inc. HIMS FY2025 $2.3B $128.4M 5.5% $4.0B 49/100
Liquidia Corporation LQDA FY2025 $158.3M -$68.9M -43.5% $5.1B 64/100
Amylyx Pharmaceuticals, Inc. AMLX FY2025 $0 -$144.7M N/A $3.4B —
Lantheus Holdings, Inc LNTH FY2025 $1.5B $233.6M 15.2% $6.7B 73/100
Alkermes Inc. plc ALKS FY2025 $1.5B $241.7M 16.4% $7.9B 72/100
Bausch Health Companies Inc BHC FY2025 $10.3B $157.0M 1.5% $3.3B 50/100

Frequently Asked Questions

Hims & Hers Health, Inc. (HIMS) reported $2.3B in total revenue for fiscal year 2025. This represents a 59.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Hims & Hers Health, Inc. (HIMS) revenue grew by 59.0% year-over-year, from $1.5B to $2.3B in fiscal year 2025.

No, Hims & Hers Health, Inc. (HIMS) reported a net loss of $190.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $128.4M, with a net profit margin of 5.5%.

Hims & Hers Health, Inc. (HIMS) reported diluted earnings per share of $0.51 for fiscal year 2025. This represents a -3.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hims & Hers Health, Inc. (HIMS) had EBITDA of $160.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Hims & Hers Health, Inc. (HIMS) had $228.6M in cash and equivalents against $972.6M in long-term debt.

Hims & Hers Health, Inc. (HIMS) had a gross margin of 73.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Hims & Hers Health, Inc. (HIMS) had an operating margin of 4.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Hims & Hers Health, Inc. (HIMS) had a net profit margin of 5.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Hims & Hers Health, Inc. (HIMS) has a return on equity of 23.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Hims & Hers Health, Inc. (HIMS) generated $57.4M in free cash flow during fiscal year 2025. This represents a -71.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Hims & Hers Health, Inc. (HIMS) generated $300.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Hims & Hers Health, Inc. (HIMS) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Hims & Hers Health, Inc. (HIMS) invested $242.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Hims & Hers Health, Inc. (HIMS) spent $90.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Hims & Hers Health, Inc. (HIMS) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.

Hims & Hers Health, Inc. (HIMS) had a debt-to-equity ratio of 1.80 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Hims & Hers Health, Inc. (HIMS) had a liabilities-to-equity ratio of 2.98 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Hims & Hers Health, Inc. (HIMS) had a return on assets of 6.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Hims & Hers Health, Inc. (HIMS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Hims & Hers Health, Inc. (HIMS) trades at 1.4x sales, its market capitalization divided by $2.9B revenue, trailing 12 months to September 30, 2026. The market capitalization is $4.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Hims & Hers Health, Inc. (HIMS) has an Altman Z-Score of 2.87, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Hims & Hers Health, Inc. (HIMS) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Hims & Hers Health, Inc. (HIMS) has an earnings quality ratio of 2.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Hims & Hers Health, Inc. (HIMS) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top